Alpha-linolenic acid inhibits RANKL-induced osteoclastogenesis in vitro and prevents inflammation in vivo
This was Citius second try for FDA approval, after the regulator rejected Lymphir in July 2023, outlining the need for enhanced product resting requirements. In its resubmitted data package, the company included findings from the from the Phase III Study 302 trial, where treatment with the drug led to an objective response rate of 36.2%, with 8.7% reaching complete response
Even individuals who eat a balanced diet may struggle with proper absorption
In muscle tissue, TNF- and FFAs impair insulin signaling by promoting increased NADH/NAD + and acetyl-CoA/CoA ratios
Licensed 503A compounders operate under state pharmacy boards and federal oversight, creating a distributed, resilient supply network
After the first year, annual TSH monitoring is typically sufficient if levels remain stable